Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | TPMT | P51580 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9364577 | 0.89 | CYP1A2 (0.96) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL16944407 | 0.89 | CYP1A2 (0.59) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL1493250 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL7365719 | 0.87 | SLC22A6 (0.77) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL7322708 | 0.83 | PDE4B (0.60) | — | |
| SCHEMBL7371556 | 0.82 | NPC1 (0.65) | TSHRALDH1A1KMT2AMEN1POLB | |
| SCHEMBL1333620 | 0.82 | CYP1A2 (0.81) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL4818731 | 0.82 | ALDH1A1 (1.00) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL6872165 | 0.82 | TSHR (0.81) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL5074372 | 0.82 | CYP1A2 (0.81) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1361210-B1 | Novel immunotherapeutic agents and their use in the reduction of cytokine levels | CELGENE CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| CN-1263731-C | Novel therapeutic immunizing agents and their use in reducing cytokine levels | CELGENE CORP (US) | 2006-07-12 | — | — | CN | disclosed |
| US-7019030-B2 | Cyano and carboxy derivatives of substituted styrenes; inhibitors of tumor necrosis factor alpha, nuclear factor kappa B, and phosphodiesterase | CELGENE CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040019106-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1361210-A2 | Novel immunotherapeutic agents and their use in the reduction of cytokine levels | CELGENE CORPORATION (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-0918746-B1 | IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20030045726-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2003-03-06 | — | — | US | disclosed |
| US-6479554-B2 | CYANO AND CARBOXY DERIVATIVES OF SUBSTITUTED STYRENES ARE INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA , NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE AND CAN BE USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, INFLAMMATORY CONDITIONS ETC. | CELGENE CORPORATION | 2002-11-12 | — | — | US | disclosed |
| US-20010056107-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2001-12-27 | — | — | US | disclosed |
| US-6262101-B1 | ALPHA-PYRROLIDINE, IMIDAZOLE AND THIOPHENE-SUBSTITUTED STYRENE DERIVATIVES; INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA, NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE | CELGENE CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6130226-A | Immunotherapeutic agents | CELGENE CORPORATION (US) | 2000-10-10 | — | — | US | disclosed |
| CN-1228080-A | Novel therapeutic immunizing agents and their use in reducing cytokine levels | CELGENE CORP (US) | 1999-09-08 | — | — | CN | disclosed |
| US-5929117-A | COMPOUNDS WHICH MEDIATE ACTION OF PHOSPHODIESTERASE AND FORMATION OF TUMOR NECROSIS FACTOR AND NUCLEAR FACTORS | CELGENE CORPORATION (US) | 1999-07-27 | — | — | US | disclosed |
| EP-0918746-A1 | IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998006692-A1 | NOVEL IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045726-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | CYP1A2 3471/4885CYP3A4 3495/4885CYP2C9 4619/4885 |
| US-20040019106-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | CYP1A2 3471/4885CYP3A4 3495/4885CYP2C9 4619/4885 |
| US-20010056107-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | CYP1A2 3471/4885CYP3A4 3495/4885CYP2C9 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.